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Background: Limited data guide radiotherapy choices for patients with brain metastases. This survey aimed to
identify patient, physician, and practice setting variables associated with reported preferences for different
treatment techniques.
Method: 277 members of the American Society for Radiation Oncology (6% of surveyed physicians) completed a
survey regarding treatment preferences for 21 hypothetical patients with brain metastases. Treatment choices
included combinations of whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery.
Vignettes varied histology, extracranial disease status, Karnofsky Performance Status (KPS), presence of neurologic
deficits, lesion size and number. Multivariate generalized estimating equation regression models were used to
estimate odds ratios.
Results: For a hypothetical patient with 3 lesions or 8 lesions, 21% and 91% of physicians, respectively, chose WBRT
alone, compared with 1% selecting WBRT alone for a patient with 1 lesion. 51% chose WBRT alone for a patient
with active extracranial disease or KPS=50%. 40% chose SRS alone for an 80 year-old patient with 1 lesion,
compared to 29% for a 55 year-old patient. Multivariate modeling detailed factors associated with SRS use,
including availability of SRS within one’s practice (OR 2.22, 95% CI 1.46-3.37).
Conclusions: Poor prognostic factors, such as advanced age, poor performance status, or active extracranial
disease, correspond with an increase in physicians’ reported preference for using WBRT. When controlling for
clinical factors, equipment access was independently associated with choice of SRS. The large variability in
preferences suggests that more information about the relative harms and benefits of these options is needed to
guide decision-making.
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Brain metastases are the most common intracranial tumor,
occurring in 20-40% of cancer patients and accounting for
20% of cancer deaths annually [1]. Median survival is 1–2
months with corticosteroids alone [2] or six months with
whole brain radiation therapy (WBRT) [3,4].
A major advance in the treatment of these patients was
addition of surgery to WBRT for treatment of a single metas-
tasis, which improved local control, distant intracranial con-
trol and neurologic survival compared to either modality
alone [5,6]. A retrospective study demonstrated differential
survival among patients undergoing WBRT according to re-
cursive partitioning analysis (RPA) classes [7]; further prog-
nostic refinements have incorporated histology and number
of lesions [8].
More recently, stereotactic radiosurgery (SRS) has
been used alone or with WBRT in patients with up to 4
metastases. When compared with WBRT alone, the
addition of SRS has improved local control, functional
autonomy and survival [5,9-11]. However, WBRT can
have significant toxicities, including fatigue, drowsiness
and suppressed appetite, and long-term difficulties
with learning, memory, concentration, and depression
[12-14]. The use of SRS alone controls limited disease
and delays the time until WBRT is necessary for dis-
tant intracranial progression [12,15,16].
In most clinical trials of therapies for brain metastases,
patients have been selected on the basis of having few me-
tastases, stable extracranial disease, and excellent perform-
ance status. In clinical practice, patients with brain
metastases are a heterogeneous population, and decision-
making requires the synthesis of multiple variables.
The objective of this survey of radiation oncologists was
to identify patient factors, physician characteristics, and
practice setting variables associated with physicians’ pre-
ferred use of different techniques for treating brain metas-
tases. This survey aimed to generate data that would allow
physicians to: (1) compare their practice patterns to a na-
tional sample; (2) assess the influence of their practice en-
vironment on treatment choice; and (3) generate new
hypotheses regarding appropriate treatment.
Methods
This project was approved by the IRB of Harvard Med-
ical School. The survey was launched online, and phys-
ician members of the American Society for Therapeutic
Radiology and Oncology (ASTRO) were emailed a re-
cruitment letter. Eligibility criteria included respondent
status as a U.S. or Canadian physician in the ASTRO
database, valid email address, and current management
of patients with brain metastases, as reflected by the
screener question. Respondents linked directly to the
survey from the email, and there was no incentive for
survey participation.Data collection
Data was de-identified and collected through the online
survey tool for one month. We emailed surveys to 4357
physician members of ASTRO on September 26, 2008, and
the survey was closed on October 26, 2008. 417 respon-
dents answered at least one question, and 277 answered all
demographic and clinical questions, for a response rate of
6%. Despite our low response rate, physician respondents
were representative of practicing radiation oncologists
when compared to respondents to the American College of
Radiology’s (ACR) Survey of Radiation Oncologists. Our
sample was similar to the ACR survey on selected charac-
teristics such as sex (73% male in our survey, 77% in ACR),
age (62% ages 35–54 in our survey, 65% in ACR) and being
in private practice (52% in our survey, 48% in ACR) [17].
However, it was not possible to assess interest in SRS or
palliative care, or use of advanced technology, among those
included in the ACR sample, which limits the comparison.
The survey was designed to: (1) describe radiation oncol-
ogists’ patterns of treatment of patients with brain metasta-
ses; and (2) identify clinical, demographic, and practice
setting factors associated with treatment patterns. To test
physician practices, a series of short hypothetical clinical
vignettes were developed to assess respondents’ preferred
treatment modalities. Vignettes have been demonstrated to
be a valid study tool when compared with actual clinical
practice patterns [18]. Treatment options for each vignette
were identical: WBRT alone; WBRT with SRS; SRS alone;
WBRT with surgery; or no treatment. We constructed 3
versions of a reference vignette: the first with 1 metastasis,
the next with 3 metastases, and one with 8 metastases.
Each reference vignette described a 55 year-old patient
with non-small cell lung cancer, inactive extracranial dis-
ease, Karnofsky Performance Status (KPS) 80%, and
asymptomatic, small brain lesion(s). For each of these 3
vignettes, we asked about 6 additional patients, modifying
a single variable: melanoma histology, active extracranial
disease, KPS 50%, presence of neurologic deficit, age of 80
years old, and large lesion (Figure 1).
Other survey items assessed factors related to the pa-
tient, physician, or practice setting. These questions
included physician demographics, practice environment,
availability of SRS, and opinions about the nature of
intracranial disease and the toxicity of its treatment. A
copy of our survey is included as supplementary material
(Additional file 1: Appendix 1). Data regarding non-
respondents were not collected.
Statistical analysis
Effects of patient clinical characteristics on treatment
choices
For the four category treatment choice responses (WBRT
alone, WBRT with SRS, SRS alone, or surgery with WBRT),
we used a series of multivariate binomial generalized
Reference Patient Characteristics 
1. NSCLC 
2. KPS 80% 
3. Inactive extracranial  (EC)  disease 
4. Age 55 
5. No neurologic deficits 
6. Small lesion size 
Patient 1 
1. Melanoma 
2. KPS 80% 
3. Inactive EC Disease 
4. Age 55 
5. No neurologic deficits 
6. Small lesion size 
Patient 2 
1. NSCLC 
2. KPS 50% 
3. Inactive EC Disease 
4. Age 55 
5. No neurologic deficits 
6. Small lesion size 
Patient 3 
1. NSCLC 
2. KPS 80% 
3. Active EC Disease 
4. Age 55 
5. No neurologic deficits 
6. Small lesion size 
Patient 4 
1. NSCLC 
2. KPS 80% 
3. Inactive EC Disease 
4. Age 80 
5. No neurologic deficits 
6. Small lesion size 
Patient 5 
1. NSCLC 
2. KPS 80% 
3. Inactive EC Disease 
4. Age 55 
5. Focal neurologic deficit 
6. Small lesion size 
Patient 6 
1. NSCLC 
2. KPS 80% 
3. Inactive EC Disease 
4. Age 55 
5. No neurologic deficits 
6. Large lesion size 
Figure 1 Variations under assumptions of 1, 3, 8 metastases in each Reference Patient. The survey sequentially varied the characteristics of
each Reference Patient to create vignettes for Patients 1–6. The effect of each variation was evaluated under assumptions of 1, 3, and 8 lesions,
respective to each vignette’s Reference Patient.
Kress et al. Radiation Oncology 2012, 7:188 Page 3 of 9
http://www.ro-journal.com/content/7/1/188estimating equation (GEE) models to estimate odds ratios
that measured the effects of each change in patients’ clinical
characteristics on the odds of each of 4 treatments choices
relative to the odds of the remaining 3 alternatives. Since
each vignette represented a repeat measurement on a phys-
ician, we considered treatment choices as correlated obser-
vations clustered within individual physicians. We used an
exchangeable correlation structure to account for the cor-
relation of physician responses between vignettes. Graphical
techniques were used to assess model adequacy. We chose
to use a series of binomial models to model a multi-
category response because of the lack of available statistical
software to implement multi-category GEE models with ex-
changeable correlation structure [19].
Effects of patient & physician characteristics on odds of
including SRS
We grouped treatment responses that included SRS (SRS
or WBRT with SRS) and compared them with the 3
remaining alternatives as a combined reference group
(WBRT, WBRT with surgery, or no treatment) in a bino-
mial GEE model that included patient clinical, physician
and practice setting characteristics as covariates. These
groupings were created to allow for exploration of factors
contributing to integrating advanced technology (SRS) into
the treatment plan, despite the fact that each treatment ap-
proach may have different clinical indications, as explored
through the above-detailed models. Working correlations
and clustering were treated as in the previous models.
All parameter estimates were tested for statistical sig-
nificance at the 0.05 level. SASW software version 9.2
was used in all analyses.
Results
Physician demographics and practice environment
The characteristics of our survey respondents are shown in
Table 1. Sixty percent of respondents were in single-specialty group practices. Most practices were hospital-
based, academic (38%) or private (30%). Seventy-six percent
of respondents treated 10–50 patients with brain metasta-
ses per year. Forty-four percent of respondents performed
SRS, while 35% had a colleague at their institution who per-
formed SRS. Sixty-one percent of respondents had LINAC-
based SRS, and 18% had no SRS equipment.
Physicians’ responses to the 21 vignettes varied sub-
stantially (Table 2). Multivariable modeling revealed clin-
ical factors influencing treatment selection (Tables 3, 4,
5; complete results in Additional file 2: Appendix 2).
Whole brain radiation therapy alone
WBRT alone was selected frequently, particularly for
patients with 8 metastases. For the 80 year-old patient
with 3 or 8 metastases, WBRT was commonly preferred
(52% and 96% vs. 21% and 91%, respectively, for the 55-
year old patient, Table 2). Even for a patient with a single
metastasis, 56% of respondents preferred WBRT alone if
that patient had KPS 50%; 51% would choose WBRT if
the patient had active extracranial disease. In adjusted
analyses, all of the clinical variables (melanoma hist-
ology, KPS 50%, active extracranial disease, age of 80
years old, presence of focal neurologic deficits, and large
lesion) were associated with a higher likelihood of
respondents preferring WBRT alone versus either SRS
alone (Table 3) or WBRT with SRS (Table 4), except for
radioresistant histology.
Addition of surgery
For the reference patient with a single metastasis, 44% of
respondents selected surgery with WBRT, although most
respondents selected a non-operative approach that
included SRS (26% WBRT with SRS; 29% SRS alone, for
a total of 55% of respondents). When the reference vi-
gnette was revised to include the presence of focal
neurologic deficits, the distribution of responses was
Table 1 Distribution of Physician Characteristics (N=277)
n %
Total











Office-based, private 60 22
Office-based, academic 14 5
Hospital-based, private 84 30
Hospital-based, academic 105 38
Veterans'/military hospital 6 2
Other 8 3









Frequency of patient follow-up
At diagnosis only 3 1
Through active treatment for brain metastases 19 7
Through one post-treatment visit 95 34
Throughout the remaining course of their disease 152 55
Other 8 3
1 Respondents were permitted to select more than one modality.
2 Personal experience includes the respondent personally being treated for
brain metastases, or having had a friend or family member treated for brain
metastases.
* Stereotactic radiosurgery.
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preferring surgery with WBRT. When considering patients
with a single, large lesion, the percent of respondents
choosing surgery with WBRT increased from 44% to 63%.
After adjusting for all other clinical factors, respondents
were more likely to choose surgery with WBRT rather than
WBRT alone for patients with large versus smaller lesions
(OR=1.9, 95% CI 1.3-2.8). For 3 or 8 lesions, age 80, active
extracranial disease, and KPS 50%, respondents were morelikely to choose WBRT alone than surgery with WBRT
(Additional file 2: Appendix 2). Melanoma histology and
presence of neurologic deficits did not correlate with
respondents’ selections.
Addition of stereotactic radiosurgery
SRS was commonly preferred by respondents for
patients with 3 lesions (23% SRS alone; 54% SRS with
WBRT, Table 2), and it largely replaced the use of sur-
gery for the older patient with a single lesion (25%
WBRT with SRS; 40% chose SRS alone). Presence of
neurological deficits and large lesion size were associated
with physicians’ preference for WBRT with SRS over
SRS alone (Table 5). However, older age, poorer per-
formance status and melanoma histology were asso-
ciated with less frequent selection of WBRT with SRS
versus SRS alone.
Use of stereotactic radiosurgery
Multivariable analysis was performed to identify which
factors were independently associated with including
SRS as part of treatment (SRS or WBRT with SRS) com-
pared to all other treatment choices (WBRT, WBRT with
surgery, no treatment), adjusting for all other character-
istics in Table 6. Number of metastases was strongly
associated with treatment preferences: after adjustment
for all other factors in the model, respondents were sig-
nificantly more likely to favor SRS for 3 lesions than for
1 (OR=2.22, 95% CI 1.96-2.51), and physicians were 5
times less likely to choose an approach that included
SRS for a patient with 8 lesions relative to patients with
1 lesion (OR=0.19, 95% CI 0.15-0.23).
Across all clinical vignettes, after adjusting for all other
factors, poor KPS (OR=0.38, 95% CI 0.31-0.46), active
extracranial disease (OR=0.56, 95% CI 0.47-0.65), and
large lesion (OR=0.58, 95% CI 0.47-0.71) remained
strongly negatively associated with the choice of SRS,
while melanoma histology (OR=2.84, 95% CI 2.45-3.29)
and advanced age (OR=1.23, 95% CI 1.07-1.41) were
positively associated with choice of SRS. Physician access
was the strongest factor associated with choosing SRS as
part of treatment. Respondents with SRS capability in
their own practice were more likely to favor its use for
hypothetical patients than those without it (OR=2.22,
95% CI 1.46-3.37). As expected, those physicians who
personally used SRS were more likely to recommend it
than those who did not have it or use it personally in
their practice (OR=3.57, 95% CI 2.42-5.26). Patient vol-
ume and physician seniority were examined, but were
not associated with SRS use.
Discussion
Treatment of patients with brain metastases is heteroge-
neous. WBRT is a standard therapy, with the addition of









WBRT* WBRT+SRS SRS† SURG+WBRT WBRT WBRT+SRS SRS SURG+WBRT WBRT WBRT+SRS SRS SURG+WBRT
Patient Characteristics
1. Reference patient 1 26 29 44 21 54 23 2 91 7 3 0
2. Melanoma Metastasis 1 17 46 36 18 44 35 3 82 11 7 0
3. KPS 50 56 17 24 3 84 7 8 1 96 2 2 0
4. Extracranial Disease 51 19 23 7 73 15 11 0 94 3 2 0




11 25 17 48 34 41 11 13 89 6 2 4
7. 3cm Brain Metastasis 11 22 5 63 42 29 2 27 72 16 0 11
1 Abbreviations as follows: Whole Brain Radiation Therapy (WBRT); Whole Brain Radiation Therapy with Stereotactic Radiosurgery (WBRT+SRS); Stereotactic Radiosurgery (SRS); Surgery with Whole Brain Radiation
Therapy (SURG+WBRT).
2 The reference patient was a 55 year-old patient with non-small cell lung cancer, inactive extracranial disease, KPS 80%, and an asymptomatic, small brain lesion.
3 Patient characteristics were varied sequentially with each patient differing by a single characteristic from the reference patient as shown in Figure 1.

















Table 3 Odds Ratios for Choice of WBRT* alone versus
SRS† Alone
WBRT* vs. SRS OR (95%CI) ††1 P
Lesions
1 (referent) 1.00
3 3.5 (2.7,4.4) <.0001
8 59.8 (29.1,122.8) <.0001
Age
55 (referent) 1.00
80 2.0 (1.5,2.6) <.0001
Extracranial Disease
None (referent) 1.00
Active 5.5 (3.7,8.1) <.0001
Focal Neurological Deficits
Asymptomatic (referent) 1.00
Symptomatic 2.7 (2.0,3.7) <.0001
Performance Status§
80 (referent) 1.00
50 6.6 (4.4,9.9) <.0001
Lesion Size
Small (referent) 1.00
Large 8.1 (5.3,12.4) <.0001
Melanoma
NSCLC¶ (referent) 1.00
Melanoma 0.5 (0.4,0.6) <.0001 Table 4 Odds Ratios for Choice of WBRT alone versus
WBRT with SRS
WBRT vs WBRT+SRS OR (95%CI) P
Lesions
1 (referent) 1.00
3 2.5 (2.0,3.1) <.0001
8 37.0 (24.6,55.5) <.0001
Age
55 (referent) 1.00
80 4.6 (3.5,6.1) <.0001
Extracranial Disease
None (referent) 1.00
Active 11.4 (8.2,15.9) <.0001
Focal Neurological Deficits
Asymptomatic (referent) 1.00
Symptomatic 1.9 (1.5,2.3) <.0001
Performance Status§
80 (referent) 1.00
50 18.0 (12.5,25.8) <.0001
Lesion Size
Small (referent) 1.00
Large 1.9 (1.4,2.6) <.0001
Melanoma
NSCLC (referent) 1.00
Melanoma 0.8 (0.7,1.0) 0.0698
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selected patients on the basis of their clinical characteristics.
One potential advantage of local therapy may be avoiding
the toxicity of WBRT [12-14]. However, SRS, when used
alone, has several disadvantages. SRS alone has been shown
to be inferior to the combination of SRS with WBRT for
durable local control and distant intracranial control [15].
When studying patients initially undergoing any local ther-
apy – surgery or SRS – more patients required salvage if
treated without WBRT [20]. Long-term cognitive outcomes
have been shown to be more closely correlated with
intracranial progression than with treatment modality, em-
phasizing the significance of intracranial control over short-
term side effects [21,22].
Given the limited scope of current studies and the vari-
ability in outcomes, National Comprehensive Cancer Net-
work (NCCN) guidelines allow for a wide range of
treatment options including WBRT, surgical resection, or
SRS, alone or in combinations [23]. Previous reviews of
treatment patterns have demonstrated stable rates of sur-
gery since the 1980s, with an increasing use of SRS [24].
Despite clinical trials limiting eligible patients to those with
limited central nervous system disease, a recent survey
demonstrated that more than half of physician respondentswould consider using SRS as an initial treatment for
patients with 5 or more intracranial lesions [25]. The
increased utilization of SRS as well as the persistent hetero-
geneity in practice may be due to the time of dissemination
of research into clinical practice, or the time to purchase
and adoption of new technologies.
With mixed evidence and a heterogeneous patient popu-
lation, treatment decision-making is complex. Significantly,
our study demonstrates that although clinical factors, such
as number of lesions and patient age, affected treatment se-
lection, physician practice environment had a strong, inde-
pendent effect on the use of SRS.
Factors related to the patient’s clinical condition affected
treatment selection. There was increased use of WBRT for
increasing number of lesions, which is consistent with the
lack of evidence to support the use of local techniques for
patients with numerous metastases. However, we observed
that a substantial proportion of physicians still chose SRS
as part of their approach for patients with multiple lesions,
particularly for patients with 3 lesions. The increased use of
SRS with 3 lesions as compared with 1 was possibly due to
the use of surgery for a substantial proportion of patients
Table 5 Odds Ratios for Choice of WBRT with SRS versus
SRS alone
WBRT+SRS vs SRS OR (95%CI) P
Lesions
1 (referent) 1.00
3 2.1 (1.7,2.6) <.0001
8 6.7 (2.4,18.5) 0.0002
Age
55 (referent) 1.00
80 0.6 (0.5,0.7) <.0001
Extracranial Disease
None (referent) 1.00
Active 0.9 (0.7,1.3) 0.6576
Focal Neurological Deficits
Asymptomatic (referent) 1.00
Symptomatic 1.4 (1.1,1.7) 0.0021
Performance Status§
80 (referent) 1.00
50 0.7 (0.5,0.9) 0.0101
Lesion Size
Small (referent) 1.00
Large 5.6 (3.2,9.8) <.0001
Melanoma
NSCLC¶ (referent) 1.00
Melanoma 0.5 (0.4,0.6) <.0001
Notes
Odds ratios (OR) are quoted with their 95% confidence intervals in
parentheses. "*" Denotes significant odds ratios at the 0.05 level.
The odds ratios compare odds of choosing each given treatment, with the
odds of choosing the treatments serving as reference categories.
* Whole brain radiation therapy.
† Stereotactic radiosurgery.
†† Confidence intervals.
§ Karnofsky Performance Status.
¶ Non-Small Cell Lung Cancer.
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WBRT in patients with 3 lesions. Interestingly, physicians
overall selected WBRT for patients with 1, 3, or 8 lesions
more often for patients who were frail (increased age, low
KPS) and might suffer increased morbidity from WBRT.
This finding was unexpected, since WBRT has been shown
to cause side effects that might be difficult for frail patients
with limited life expectancy to tolerate, such as increasing
fatigue, worsening physical function, and deterioration of
appetite [7,14,26]. Additional clinical factors may influence
treatment selection, but were not addressed in this study,
including tumor location and surgical accessibility; add-
itional treatment options not evaluated include the use of
SRS in combination with surgery, chemotherapy, and the
role of hospice.
Practice environment and clinical expertise also influ-
enced the use of SRS, even when controlling for clinicalfactors. Although practice type was not associated with the
preference for SRS, the availability of SRS was significantly
associated with its use, indicating that patients are more
likely to receive this treatment if the physician they see
practices it herself or has it available within her practice.
This pattern of care could lead to under- or over-utilization
of SRS: patients may have treatment guided more by a pro-
vider’s practice than by the patient’s clinical condition. Pre-
vious studies have demonstrated the association of
physician specialization, board certification, treatment vol-
ume and time in practice with other cancer-related treat-
ment decisions [27,28]. For example, diagnostic imaging
use has increased when such imaging is performed at a
self-referred facility [29]. Similarly, radiation oncologists
may be prescribing complex treatment approaches more
frequently when they have access to the facilities or equip-
ment. Alternatively, this propensity for increased use of
SRS with easy access may relate to physicians’ familiarity
with their own clinical outcomes when using new technol-
ogy. Our respondents may also have rates of access to SRS
that are not comparable to those available nationwide, since
the ACR survey did not report on the availability of SRS
equipment.
Our study has several limitations due to its reliance on
physician self-report as a proxy for practice, its timing,
and the limited number of respondents. Clinical scenar-
ios were hypothetical and treatment options were lim-
ited. Although physician surveys have shown a strong
correlation between vignettes and actual practice [18],
further objective validation of these data would be desir-
able, as the vignettes used in this survey were novel.
Respondents to this survey were dominantly radiation
oncologists, whose treatment decisions may be greatly
impacted by other members of the inter-disciplinary on-
cology team not represented in this survey. Rates of
radiosurgery utilization more than doubled between
2000 and 2005, so continued increases in the use of
radiosurgery could have occurred since the completion
of this survey [30]. Additional research has been pub-
lished since 2008 that may have resulted in further shifts
in practice patterns.
The limited number of respondents to our survey lim-
its the generalizability of our findings. The response rate
of 6% may indicate that the practice patterns outlined in
this study are specific to a subgroup of clinicians with
particular interest or expertise in radiosurgery and may
not be indicative of global patterns of care. Although
respondents were similar to those in the ACR survey,
the comparison is limited due to the nature of the vari-
ables available; key issues, such as expertise with SRS or
volume of patients brain metastases, were not available
in the ACR survey for comparison. However, ours is the
first study to document practice patterns using vignettes
in this clinical setting.
Table 6 Results of logistic regression model showing the
reported use of SRS* as part of treatment for brain
metastases according to multiple clinical,
sociodemographic, and practice setting factors2
Including SRS 1 p-value
Lesions
1 (reference) 1.00
3 2.22 (1.96-2.51) <.0001
8 0.19 (0.15-0.23) <.0001
Karnofsky Performance Status
80 (reference) 1.00
50 0.38 (0.31-0.46) <.0001
Tumor Characteristics
Lung cancer (reference) 1.00
Melanoma histology 2.84 (2.45-3.29) <.0001
Extracranial disease
No extracranial disease (reference) 1.00
Active extracranial disease 0.56 (0.47-0.65) <.0001
Age
55 (reference) 1.00
80 1.23 (1.07-1.41) 0.0034
Focal neurological deficits
None (reference) 1.00
Present 0.99 (0.85-1.14) 0.8492
Lesion size
Small (reference) 1.00
Large 0.58 (0.47-0.71) <.0001
Race
Other (reference) 1.00
White 1.13 (0.83-1.52) 0.4415
Gender
Male (reference) 1.00
Female 1.07 (0.81-1.40) 0.6287
Specialization of Practice Setting
Multispecialty (reference) 1.00
Single 1.07 (0.82-1.39) 0.6036
Access to SRS
None (reference) 1.00
Personal use 3.57 (2.42-5.26) <.0001
Available in practice 2.22 (1.46-3.37) 0.0002
WBRT † Adverse Effects Severity
None (reference) 1.00
At least minimal severity 0.55 (0.40-0.77) 0.0004
SRS Adverse Effects Severity
None (reference) 1.00
At least minimal severity 0.90 (0.53-1.51) 0.6804
Personal Experience with Brain Metastases
Table 6 Results of logistic regression model showing the
reported use of SRS* as part of treatment for brain
metastases according to multiple clinical,
sociodemographic, and practice setting factors2
(Continued)
Some personal (reference) 3 1.00
Patients only 1.10 (0.81-1.50) 0.5369
1 Including SRS was defined as either use of SRS alone or with Whole Brain
Radiation Therapy (WBRT).
2 The reference patient was a 55 year-old patient with non-small cell lung
cancer, inactive extracranial disease, KPS 80%, and an asymptomatic, small
brain lesion.
3 Personal experience includes the respondent personally being treated for
brain metastases, or having had a friend or family member treated for brain
metastases.
* Stereotactic radiosurgery.
† Whole brain radiation therapy.
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Although many patients with cancer develop brain me-
tastases, there is little data to guide treatment decisions.
Our study demonstrates the significant heterogeneity
among radiation oncologists in general clinical practice
even for patients with identical clinical characteristics.
Certain non-clinical factors, such as access to SRS, ap-
pear to be key drivers of use of advanced technology.
This finding raises the question about what additional
incentives could be driving treatment selection in the
absence of gold-standard evidence of the superiority of a
single approach over other alternatives. Our findings
from this survey also underscore the likely uncertainty
or disagreement that may exist among radiation oncolo-
gists about the relative harms and benefits of different
treatment approaches. This uncertainty is likely related
to the lack of prospective randomized studies that com-
pare specific single- and multi-modality approaches for
the treatment of brain metastases. More research is
needed that directly compares the effectiveness of these
approaches for a variety of different clinical circum-
stances. It would also be important to investigate
underlying non-clinical factors, such as physician envir-
onment, reimbursement, and technology access, which
likely contribute to observed heterogeneity of care for
patients with brain metastases.Additional files
Additional file 1: Appendix 1. Complete physician survey.
Additional file 2: Appendix 2. Odds Ratios and Confidence Intervals
Comparing the Odds of Treatment Choices for Different Patient
Characteristics.
Abbreviations
WBRT: Whole brain radiation therapy; SRS: Stereotactic radiosurgery;
KPS: Karnofsky performance status; RPA: Recursive partitioning analysis;
ASTRO: American society for therapeutic radiation oncology; ACR: American
Kress et al. Radiation Oncology 2012, 7:188 Page 9 of 9
http://www.ro-journal.com/content/7/1/188college of radiology; GEE: Generalized estimating equation; NCCN: National
comprehensive cancer network.
Competing interests
Dr. Ramakrishna has received speaker’s honoraria from and prepared
educational materials for Brainlab Ag, Heimstetten, Germany. The remaining
authors have no conflicts of interest to disclose.
Authors’ contributions
NR and MK conceived of the study, designed the survey, and completed
data collection. MK, KU, SM, and AP performed statistical analysis and data
interpretation. MK, SM, and AP drafted the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
Neil Samuel Ghiso Foundation Fellowship.
Author details
1Department of Radiation Oncology, Georgetown University Medical Center,
3800 Reservoir Road, Washington, D.C, USA. 2Department of Radiation
Oncology, MD Anderson Cancer Center Orlando, Orlando, Florida, USA.
3Cancer Control Program, Lombardi Comprehensive Cancer Center,
Georgetown University Medical Center, Washington D.C, USA.
Received: 10 August 2012 Accepted: 11 October 2012
Published: 8 November 2012
References
1. Nussbaum ES, Djalilian HR, Cho KH, et al: Brain metastases. Histology,
multiplicity, surgery, and survival. Cancer 1996, 78:1781–1788.
2. Weissman DE: Glucocorticoid treatment for brain metastases and
epidural spinal cord compression: a review. J Clin Oncol 1988, 6:543–551.
3. Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: final
results of the first two studies by the Radiation Therapy Oncology
Group. Int J Radiat Oncol Biol Phys 1980, 6:1–9.
4. Rades D, Kieckebusch S, Haatanen T, et al: Surgical resection followed by
whole brain radiotherapy versus whole brain radiotherapy alone for
single brain metastasis. J Radiat Oncol Biol Phys 2008, 70:1319–1324.
5. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the
treatment of single metastases to the brain: a randomized trial. JAMA
1998, 280:1485–1489.
6. Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the
treatment of single metastases to the brain. N Engl J Med 1990, 322:494–500.
7. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of
prognostic factors in three Radiation Therapy Oncology Group (RTOG)
brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745–751.
8. Sperduto PW, Chao ST, Sneed PK, et al: Diagnosis-specific prognostic
factors, indexes, and treatment outcomes for patients with newly
diagnosed brain metastases: a multi-institutional analysis of 4,259
patients. Int J Radiat Oncol Biol Phys 2010, 77:655–661.
9. Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus
whole brain radiotherapy versus radiotherapy alone for patients with
multiple brain metastases. Int J Radiat Oncol Biol Phys 1999, 45:427–434.
10. Sanghavi SN, Miranpuri SS, Chappell R, et al: Radiosurgery for patients with
brain metastases: a multi-institutional analysis, stratified by the RTOG
recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 2001,
51:426–434.
11. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy
with or without stereotactic radiosurgery boost for patients with one to
three brain metastases: phase III results of the RTOG 9508 randomised
trial. Lancet 2004, 363:1665–1675.
12. Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with
brain metastases treated with radiosurgery or radiosurgery plus
whole-brain irradiation: A randomised controlled trial. Lancet Oncology
2009, 10:1037–1044.
13. Kondziolka D, Niranjan A, Flickinger JC, et al: Radiosurgery with or without
whole-brain radiotherapy for brain metastases: The patients’ perspective
regarding complications. Am J Clin Oncol 2005, 28:173–179.
14. Chow E, Davis L, Holden L, et al: Propsective assessment of patient-rated
symptoms following whole brain radiotherapy for brain metastases.
Journal of Pain and Symptom Management 2005, 30:19–23.15. Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus
whole-brain radiation therapy vs stereotactic radiosurgery alone for
treatment of brain metastases: a randomized controlled trial. JAMA
2006, 295:2486–2491.
16. Sneed PK, Suh JH, Goetsch SF, et al: A multi-institutional review of
radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the
initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002,
53:519–526.
17. Lewis RS, Sunshine JH: Radiation Oncologists in the United States. Int J
Radiat Oncol Biol Phys 2007, 69:518–527.
18. Peabody JW, Luck J, Glassman P, et al: Measuring the quality of physician
practice by using clinical vignettes: a prospective validation study. Ann
Intern Med 2004, 141:771–780.
19. Kuss O, McLerran D: A note on the estimation of the multinomial logistic
model with correlated responses in SAS Computer Methods and
Programs. Biomedicine 2007, 87:262–269.
20. Kocher M, Soffiette R, Abacioglu U, et al: Adjuvant whole-brain
radiotherapy versus observation after radiosurgery or surgical resection
of one to three cerebral metastases: results of the EORTC 22952–26001
study. J Clin Oncol 2011, 29:134–141.
21. Aoyama H, Tago M, Kato N, et al: Neurocognitive function of patients with
brain metastasis who received either whole brain radiotherapy plus
stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol
Phys 2007, 68:1388–1395.
22. Regine WF, Scott C, Murray K, et al: Neurocognitive outcome in brain
metastases patients treated with accelerated-fractionation vs.
accelerated-hyperfractionated radiotherapy: An analysis from Radiation
Therapy Oncology Group Study 91–04. Int J Radiat Oncol Biol Phys 2001,
51:711–717.
23. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines
in Oncology (NCCN Guidelines): Central Nervous System Cancers Version
2.2011.: National Comprehensive Cancer Network; 2001.
24. Nieder C, Spanne O, Mehta MP, et al: Presentation, patterns of care, and
survival in patients with brain metastases: what has changed in the last
20 years?. Cancer 2010, Epub ahead of print.
25. Knisely JP, Yamamoto M, Gross CP, et al: Radiosurgery alone for 5 or more
brain metastases: expert opinion survey. J Neurosurg 2010, 113:84–89.
26. Pesce GA, Klingbiel D, Ribi K, et al: Outcome, quality of life and cognitive
function of patients with brain metastases from non-small cell lung
cancer treated with whole brain radiotherapy combined with gefitinib
or temozolomide. A randomised phase II trial of the Swiss Group for
Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2012, 48:377–384.
27. Wasif N, Tamurian RM, Christensen S, et al: Influence of Specialty and
Clinical Experience on Treatment Sequencing in the Multimodal
Management of Soft Tissue Extremity Sarcoma. Ann Surg Oncol 2011,
19:504–510.
28. Chuah TK, Lee T, Wirtzfeld D, et al: Management of primary rectal cancer
by surgeons in Atlantic Canada: results of a regional survey. Can J Surg
2010, 53:396–402.
29. Kilani RK, Paxton BE, Stinnett SS, et al: Self-referral in medical imaging: a
meta-analysis of the literature. J Am Coll Radiol 2011, 8:469–476.
30. Halasz LM, Weeks JC, Neville BA, et al: Use of Stereotactic Radiosurgery For
Brain Metastases: A SEER-Medicare Analysis.: Poster Presentation, ASTRO; 2011.
doi:10.1186/1748-717X-7-188
Cite this article as: Kress et al.: Physician self-reported treatment of
brain metastases according to patients’ clinical and demographic
factors and physician practice setting. Radiation Oncology 2012 7:188.
